High-Dose Chemotherapy for Primary Central Nervous System Lymphoma

Almost 60% of patients older than 65 achieved a 12-month progression-free survival after intensive induction therapy and consolidative autologous stem-cell transplantation.

Outcomes for primary central nervous system lymphoma (PCNSL) have been improved via intensive immunochemotherapy plus autologous stem-cell transplantation (ASCT) consolidation, although clinicians have been concerned that older patients cannot benefit from this regimen due to underlying comorbidities and treatment-related toxicities. In MARTA, a phase 2, prospective, single-arm, German multicenter trial, researchers investigated the use of CNS-penetrating high-dose therapy and ASCT consolidation in 54 fit patients 65 years or older with newly diagnosed PCNSL. Eligible patients received two cycles of high-dose methotrexate and cytarabine plus rituximab, followed by a conditioning regimen of rituximab, thiotepa, and busulfan and then by ASCT …

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

High-Dose Chemotherapy for Primary Central Nervous System Lymphoma

Topics

Reviewing Author